Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors DOI Creative Commons
Shovan Dutta, Anirban Ganguly, Kaushiki Chatterjee

и другие.

Biology, Год журнала: 2023, Номер 12(2), С. 218 - 218

Опубликована: Янв. 30, 2023

Immune checkpoint blockade (ICB) has emerged as a novel therapeutic tool for cancer therapy in the last decade. Unfortunately, small number of patients benefit from approved immune inhibitors (ICIs). Therefore, multiple studies are being conducted to find new ICIs and combination strategies improve current ICIs. In this review, we discuss some checkpoints, such PD-L1, PD-1, CTLA-4, also highlight newer emerging For instance, HLA-E, overexpressed by tumor cells, represents an immune-suppressive feature binding CD94/NKG2A, on NK T cells. NKG2A recruits CD8+ cells activates decrease burden. NKG2D acts cell activating receptor that can be potential ICI. The adenosine A2A A2B receptors, CD47-SIRPα, TIM-3, LAG-3, TIGIT, VISTA targets contribute immunoresistance have been considered clinical trials. Their antitumor immunosuppressive functions used develop blocking antibodies. PARPs, mARTs, B7-H3 other immunosuppression. Additionally, miRNA, mRNA, CRISPR-Cas9-mediated immunotherapeutic approaches investigated with great interest. Pre-clinical project these candidates different types their robust modulation.

Язык: Английский

mRNA vaccines for infectious diseases: principles, delivery and clinical translation DOI Open Access
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead

и другие.

Nature Reviews Drug Discovery, Год журнала: 2021, Номер 20(11), С. 817 - 838

Опубликована: Авг. 25, 2021

Язык: Английский

Процитировано

1022
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways DOI
Lukas Kraehenbuehl, Chien‐Huan Weng, Shabnam Eghbali

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2021, Номер 19(1), С. 37 - 50

Опубликована: Сен. 27, 2021

Язык: Английский

Процитировано

604
Neoantigens: promising targets for cancer therapy DOI Creative Commons
Na Xie, Guobo Shen, Wei Gao

и другие.

Signal Transduction and Targeted Therapy, Год журнала: 2023, Номер 8(1)

Опубликована: Янв. 6, 2023

Abstract Recent advances in neoantigen research have accelerated the development and regulatory approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy antibody-based therapies, especially for solid tumors. Neoantigens are newly formed antigens generated by cells as a result various tumor-specific alterations, such genomic mutation, dysregulated RNA splicing, disordered post-translational modification, integrated viral open reading frames. recognized non-self trigger an immune response that is not subject to central peripheral tolerance. The quick identification prediction neoantigens been made possible advanced next-generation sequencing bioinformatic technologies. Compared tumor-associated antigens, highly immunogenic provide emerging targets personalized serve prospective predictors survival prognosis checkpoint blockade responses. therapies will be aided understanding mechanism underlying neoantigen-induced anti-tumor streamlining process neoantigen-based immunotherapies. This review provides overview on characterization outlines clinical applications immunotherapeutic strategies based neoantigens. We also explore their current status, inherent challenges, translation potential.

Язык: Английский

Процитировано

504
Cancer vaccines as promising immuno-therapeutics: platforms and current progress DOI Creative Commons
Jian Liu,

Minyang Fu,

Manni Wang

и другие.

Journal of Hematology & Oncology, Год журнала: 2022, Номер 15(1)

Опубликована: Март 18, 2022

Abstract Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy of solid tumors. Cancer stimulates anti-tumor immunity antigens, which could be delivered form whole cells, peptides, nucleic acids, etc . Ideal vaccines overcome immune suppression tumors and induce both humoral cellular immunity. In this review, we introduced working mechanism summarized four platforms for development. We also highlighted research vaccines, especially focusing their application efficacy, might hopefully facilitate future design vaccine.

Язык: Английский

Процитировано

503
RNA-based therapeutics: an overview and prospectus DOI Creative Commons
Yiran Zhu, Liyuan Zhu, Xian Wang

и другие.

Cell Death and Disease, Год журнала: 2022, Номер 13(7)

Опубликована: Июль 23, 2022

Abstract The growing understanding of RNA functions and their crucial roles in diseases promotes the application various RNAs to selectively function on hitherto “undruggable” proteins, transcripts genes, thus potentially broadening therapeutic targets. Several RNA-based medications have been approved for clinical use, while others are still under investigation or preclinical trials. Various techniques explored promote intracellular trafficking metabolic stability, despite significant challenges developing therapeutics. In this review, mechanisms action, challenges, solutions, therapeutics comprehensively summarized.

Язык: Английский

Процитировано

394
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment DOI Open Access
Cathrine Lund Lorentzen, John B.A.G. Haanen, Özcan Met

и другие.

The Lancet Oncology, Год журнала: 2022, Номер 23(10), С. e450 - e458

Опубликована: Сен. 26, 2022

Язык: Английский

Процитировано

340
mRNA-based cancer therapeutics DOI
Chuang LIU,

Qiangqiang Shi,

Xiangang Huang

и другие.

Nature reviews. Cancer, Год журнала: 2023, Номер 23(8), С. 526 - 543

Опубликована: Июнь 13, 2023

Язык: Английский

Процитировано

240
COVID-19 mRNA vaccines: Platforms and current developments DOI Creative Commons
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic

и другие.

Molecular Therapy, Год журнала: 2022, Номер 30(5), С. 1850 - 1868

Опубликована: Фев. 19, 2022

Since the first successful application of messenger ribonucleic acid (mRNA) as a vaccine agent in preclinical study nearly 30 years ago, numerous advances have been made field mRNA therapeutic technologies. This research uncovered unique favorable characteristics vaccines, including their ability to give rise non-toxic, potent immune responses and potential design upscale them rapidly, making excellent candidates during coronavirus disease 2019 (COVID-19) pandemic. Indeed, two vaccines against COVID-19 receive accelerated regulatory authorization were nucleoside-modified which showed more than 90% protective efficacy symptomatic severe acute respiratory syndrome 2 (SARS-CoV-2) infection alongside tolerable safety profiles pivotal phase III clinical trials. Real-world evidence following deployment global vaccination campaigns utilizing has bolstered trial further illustrated that this technology can be used safely effectively combat COVID-19. unprecedented success also emphasized broader new drug class, not only for other infectious diseases, but indications, such cancer inherited diseases. review presents brief history current status development four platforms, unmodified mRNA, circular RNA, self-amplifying well an overview recent progress vaccines. We discuss anticipated challenges these technologies, may important future endeavors applications.

Язык: Английский

Процитировано

212
Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy DOI Creative Commons
Qiang Lü,

Dongquan Kou,

Shenghan Lou

и другие.

Journal of Hematology & Oncology, Год журнала: 2024, Номер 17(1)

Опубликована: Апрель 2, 2024

Abstract Cancer immunotherapy and vaccine development have significantly improved the fight against cancers. Despite these advancements, challenges remain, particularly in clinical delivery of immunomodulatory compounds. The tumor microenvironment (TME), comprising macrophages, fibroblasts, immune cells, plays a crucial role response modulation. Nanoparticles, engineered to reshape TME, shown promising results enhancing by facilitating targeted These nanoparticles can suppress fibroblast activation, promote M1 macrophage polarization, aid dendritic cell maturation, encourage T infiltration. Biomimetic further enhance increasing internalization agents cells such as cells. Moreover, exosomes, whether naturally secreted body or bioengineered, been explored regulate TME immune-related affect cancer immunotherapy. Stimuli-responsive nanocarriers, activated pH, redox, light conditions, exhibit potential accelerate co-application with checkpoint inhibitors is an emerging strategy boost anti-tumor immunity. With their ability induce long-term immunity, nanoarchitectures are structures development. This review underscores critical overcoming current driving advancement modification.

Язык: Английский

Процитировано

165
Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies DOI Creative Commons
Hongjian Li, Kun Peng, Kai Yang

и другие.

Theranostics, Год журнала: 2022, Номер 12(14), С. 6422 - 6436

Опубликована: Янв. 1, 2022

Rationale: Messenger RNA (mRNA) vaccine outperforms other kinds of cancer immunotherapy due to its high response rates, easy preparation, and wide applicability, which is considered as one the most promising forms next-generation therapies.However, inherent instability insufficient protein expression duration mRNA limit efficacy widespread application vaccine.Methods: Here, we first tested possibility a novel circular (circRNA) platform for compare with linear RNA.Then, developed lipid nanoparticle (LNP) system circRNA delivery in vitro vivo.Next, innate adaptive immune circRNA-LNP complex was evaluated vivo.The anti-tumor further confirmed three tumor models.Finally, combination therapy adoptive cell transfer investigated late-stage model. Results:We successfully increased stability by circularizing molecules form highly stable exhibited durable ability.By encapsulating antigen-coding LNP enabling vivo expression, established platform, capable triggering robust activation showed superior multiple mouse models.Conclusions: Overall, our provides prospect development vaccines range hard-to-treat malignancies.

Язык: Английский

Процитировано

128